Regulus Therapeutics Inc (NASDAQ: RGLS) has fallen $0.0187 (6.58%) and is currently sitting at $0.27, as of 12:06:01 est on June 22.

555,476 shares have been traded today.

The Company has risen 21.44% over the last 5 days and shares gained 25.74% over the last 30 days.

Regulus is set to release earnings on 2022-08-09.

For technical charts, analysis, and more on Regulus visit the company profile.

About Regulus Therapeutics Inc

Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in La Jolla, CA.

To get more information on Regulus Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Regulus Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

The Best Laid Plans of Mice and Men — Part II

Why I’m Buying the 'New' Value Stocks

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan

'Goldilocks' Stocks Will Define This Decade